P. Murali Doraiswamy
Professor of Psychiatry and Behavioral Sciences
Murali Doraiswamy MBBS FRCP is Professor of Psychiatry and Professor in Medicine at Duke University School of Medicine where he is a highly cited physician scientist at the Duke Institute for Brain Sciences. He is also a Senior Fellow at the Duke Center for the Study of Aging and an Affiliate Faculty at the Duke Center for Precision Medicine and Applied Genomics as well as the Duke Microbiome Center. He directs a clinical trials unit that has been involved in the development of many modern diagnostic tests, apps, algorithms, and therapeutics in wide use today. Prof Doraiswamy has been an advisor to leading government agencies, businesses and advocacy groups including the NIH, FDA, and WHO as well as numerous life science companies. He has served as the chair of the World Economic Forum’s Global Agenda Council on Brain Research and co-chaired the innovation advisory council for one of the world’s largest social impact funds dedicated to promoting innovative solutions to reverse age related disorders. He has lectured at leading global forums to advance the forefront of aging and neuroscience research. Moreover as an investigator on numerous landmark trials and co-author on more than 400 publications, he has received several awards in recognition of his scientific work. Additionally, he is a leading advocate for increasing funding for brain and behavioral research to help address great looming challenges in society posed by modern developments in the 21st century. His research has been featured in media outlets such as BBC, The New York Times, Scientific American, The Wall Street Journal, National Public Radio, CBS Evening news, The Dr Oz Show, Oprah, and TIME. He has appeared in acclaimed documentaries such as (Dis)Honesty: The Truth about Lies and Mysteries of the Brain. He is the co-author of a popular book The Alzheiemr's Action Plan. Prof. Doraiswamy also serves on the board of several global charities.
Racial and Geographic Disparities in Risk and Survival of Alzheimer's Disease and Related Dementias: Effects of Over/UnderDiagnosis and Disease Severity awarded by National Institutes of Health (Senior Investigator). 2019 to 2024
Duke Creating ADRD Researchers for the Next Generation - Stimulating Access to Research in Residency Program (CARiNG-StARR)" awarded by National Institutes of Health (Preceptor). 2020 to 2023
Metabolomic Signatures for Disease Sub-classification and Target Prioritization in AMP-AD awarded by National Institutes of Health (Co Investigator). 2018 to 2023
Evaluating Effects in the Relationship between Traumatic Brain Injury and Alzheimer's Disease: Epidemiological Determinants, Their Health-Related Causes and the Resulting Disparities awarded by United States Army Medical Research Acquisition Activity (Senior Investigator). 2020 to 2023
Gut Liver Brain Biochemical Axis in Alzheimer's Disease awarded by National Institutes of Health (Co Investigator). 2018 to 2023
Metabolic Networks and Pathways Predictive of Sex Differences in AD Risk and Responsiveness to Treatment awarded by National Institutes of Health (Co Investigator). 2018 to 2023
Genetic Modulations of Morbidity Compression: A Population-Based Study awarded by National Institutes of Health (Investigator). 2021 to 2022
Sex Differences in Alzheimer's Disease Progression: Framingham Heart Study awarded by Cure Alzheimer's Fund (Principal Investigator). 2021 to 2022
Phase 3 Clinical Trial for Agitation in Alzheimer's 15-AVP-786-301 awarded by Avanir Pharmaceuticals (Principal Investigator). 2016 to 2021
Phase 3 Clinical Trial for Agitation in Alzheimer's 15-AVP-786-303 awarded by Avanir Pharmaceuticals (Principal Investigator). 2016 to 2021
Baloni, Priyanka, et al. “Metabolic Network Analysis Reveals Altered Bile Acid Synthesis and Metabolism in Alzheimer's Disease.” Cell Rep Med, vol. 1, no. 8, Nov. 2020, p. 100138. Pubmed, doi:10.1016/j.xcrm.2020.100138. Full Text
Franzmeier, Nicolai, et al. “Higher CSF sTREM2 attenuates ApoE4-related risk for cognitive decline and neurodegeneration.” Mol Neurodegener, vol. 15, no. 1, Oct. 2020, p. 57. Pubmed, doi:10.1186/s13024-020-00407-2. Full Text
Blumenthal, James A., et al. “The role of comorbid anxiety in exercise and depression trials: Secondary analysis of the SMILE-II randomized clinical trial.” Depress Anxiety, Aug. 2020. Pubmed, doi:10.1002/da.23088. Full Text
Bernath, Megan M., et al. “Serum triglycerides in Alzheimer disease: Relation to neuroimaging and CSF biomarkers.” Neurology, vol. 94, no. 20, May 2020, pp. e2088–98. Pubmed, doi:10.1212/WNL.0000000000009436. Full Text
Arnold, Matthias, et al. “Sex and APOE ε4 genotype modify the Alzheimer's disease serum metabolome.” Nature Communications, vol. 11, no. 1, Mar. 2020, p. 1148. Epmc, doi:10.1038/s41467-020-14959-w. Full Text
Blumenthal, James A., et al. “Longer Term Effects of Diet and Exercise on Neurocognition: 1-Year Follow-up of the ENLIGHTEN Trial.” J Am Geriatr Soc, vol. 68, no. 3, Mar. 2020, pp. 559–68. Pubmed, doi:10.1111/jgs.16252. Full Text
Bodner, Kaylee A., et al. “Advancing Computerized Cognitive Training for MCI and Alzheimer's Disease in a Pandemic and Post-pandemic World.” Front Psychiatry, vol. 11, 2020, p. 557571. Pubmed, doi:10.3389/fpsyt.2020.557571. Full Text
Doraiswamy, P. Murali, et al. “Artificial intelligence and the future of psychiatry: Insights from a global physician survey.” Artif Intell Med, vol. 102, Jan. 2020, p. 101753. Pubmed, doi:10.1016/j.artmed.2019.101753. Full Text
Smith, Patrick J., et al. “Metabolic and Neurocognitive Changes Following Lifestyle Modification: Examination of Biomarkers from the ENLIGHTEN Randomized Clinical Trial.” J Alzheimers Dis, vol. 77, no. 4, 2020, pp. 1793–803. Pubmed, doi:10.3233/JAD-200374. Full Text
Sabbagh, M. N., et al. “Early Detection of Mild Cognitive Impairment (MCI) in an At-Home Setting.” J Prev Alzheimers Dis, vol. 7, no. 3, 2020, pp. 171–78. Pubmed, doi:10.14283/jpad.2020.22. Full Text
Harenberg, S., et al. “Knowledge-guided maximal clique enumeration.” Lecture Notes in Computer Science (Including Subseries Lecture Notes in Artificial Intelligence and Lecture Notes in Bioinformatics), vol. 10086 LNAI, 2016, pp. 604–18. Scopus, doi:10.1007/978-3-319-49586-6_43. Full Text
Doraiswamy, P. Murali, et al. “Preimplantation Genetic Diagnosis (PGD) for Familial Alzheimer's Disease Due To PSEN1 Mutation.” Annals of Neurology, vol. 76, WILEY-BLACKWELL, 2014, pp. S90–S90.
Hochstetler, Helen, et al. “Relationship of Florbetapir F18 PET Amyloid Plaque Neuroimaging with Future Cognitive Decline over 36 Months.” The American Journal of Geriatric Psychiatry, vol. 21, no. 3, Elsevier BV, 2013, pp. S136–S136. Crossref, doi:10.1016/j.jagp.2012.12.180. Full Text
Witte, Michael, et al. “Florbetapir PET Imaging Predicts Postmortem Amyloid Burden in Alzheimer's Disease Despite Presence of Other Neuropathologies.” The American Journal of Geriatric Psychiatry, vol. 21, no. 3, Elsevier BV, 2013, pp. S138–39. Crossref, doi:10.1016/j.jagp.2012.12.183. Full Text
Sheldon, F. C., et al. “Disruption of Functional Brain Connections in Alzheimer's Disease.” Journal of Nuclear Medicine, vol. 51, no. 5, SOC NUCLEAR MEDICINE INC, 2010, pp. 828–29.
Doraiswamy, P. Murali, et al. “In Cognitively Healthy and Mildly Impaired Individuals Florbetapir F 18 PET Measures of Amyloid Deposition Correlate with the Degree of Functional Impairment Assessed Six Months Later.” Neurology, vol. 74, no. 9, LIPPINCOTT WILLIAMS & WILKINS, 2010, pp. A338–A338.
Doraiswamy, P. Murali, et al. “Atypical antipsychotic drugs and diabetes mellitus in the USFDA adverse event reporting system (AERS) database in pediatric and adult patients.” Biological Psychiatry, vol. 63, no. 7, ELSEVIER SCIENCE INC, 2008, pp. 283S-284S.
Kaddurah-Daouk, Rima, et al. “Metabolomic mapping of schizophrenia and atypical antipsychotic effects.” Biological Psychiatry, vol. 61, no. 8, ELSEVIER SCIENCE INC, 2007, pp. 164S-164S.
Szarfman, A., et al. “Risperidone and pituitary tumors: a pharmacovigilance study.” Bipolar Disorders, vol. 7, BLACKWELL PUBLISHING, 2005, pp. 116–17.
Pomara, N., et al. “Elevated plasma A beta(1-42) in geriatric depression.” Biological Psychiatry, vol. 57, no. 8, ELSEVIER SCIENCE INC, 2005, pp. 200S-200S.